Freedom Investment Management Inc. Acquires Shares of 15,279 ADMA Biologics Inc $ADMA

Key Points

• Freedom Investment Management Inc. has acquired a new stake in ADMA Biologics, purchasing 15,279 shares valued at approximately $303,000.
• ADMA Biologics reported earnings of $0.15 per share for the quarter, exceeding expectations and reflecting a year-over-year revenue increase of 13.8%.
• Analysts have mixed ratings on ADMA with a consensus of "Buy," while Raymond James Financial raised the price target from $25.00 to $32.00.

Freedom Investment Management Inc. purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 15,279 shares of the biotechnology company's stock, valued at approximately $303,000.

Other large investors have also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ acquired a new position in ADMA Biologics in the 1st quarter valued at approximately $35,000. SVB Wealth LLC acquired a new position in ADMA Biologics in the 1st quarter valued at approximately $35,000. Smartleaf Asset Management LLC raised its holdings in ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 1,493 shares in the last quarter. Tsfg LLC acquired a new position in ADMA Biologics in the 1st quarter valued at approximately $51,000. Finally, Brooklyn Investment Group raised its holdings in ADMA Biologics by 28,655.6% in the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 2,579 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of "Buy" and an average target price of $27.67.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 455,621 shares of company stock worth $9,461,633 in the last three months. Insiders own 3.70% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA traded down $0.12 during mid-day trading on Monday, reaching $17.26. The company had a trading volume of 2,527,726 shares, compared to its average volume of 3,391,207. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The company's 50-day moving average is $17.76 and its 200-day moving average is $18.93. The company has a market capitalization of $4.12 billion, a P/E ratio of 20.07 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same period in the prior year, the firm posted $0.13 EPS. ADMA Biologics's quarterly revenue was up 13.8% compared to the same quarter last year. On average, equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.